Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by HC Wainwright

Innate Pharma (NASDAQ:IPHA) was upgraded by HC Wainwright from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on IPHA. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down previously from $10.00) on shares of Innate Pharma in a research note on Thursday, September 18th. Leerink Partnrs lowered shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a research report on Wednesday, October 8th. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of Innate Pharma in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.00.

Innate Pharma Stock Performance

Shares of NASDAQ IPHA opened at $1.99 on Wednesday. The business has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $2.04. Innate Pharma has a one year low of $1.29 and a one year high of $3.51.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.